Search results
Showing 1231 to 1245 of 1766 results for patient safety
Question Evidence on the safety of repetitive short-pulse transscleral cyclophotocoagulation for glaucoma shows no major...
Recommendation ID IPG755/1 Question Evidence on the safety and efficacy of percutaneous thoracic duct embolisation for persistent chyle
Recommendation ID IPG760/1 Question Evidence on the safety and efficacy of daytime intraoral neuromuscular electrical tongue stimulation
quality and quantity. Short-term evidence shows no major safety concerns, but long-term evidence on safety is limited in...
Question Evidence on the safety of transcranial magnetic stimulation for obsessive-compulsive disorder raises no major...
NICE has developed a medtech innovation briefing (MIB) on clonoSEQ for minimal residual disease assessment in multiple myeloma, acute lymphoblastic leukaemia and chronic lymphocytic leukaemia .
This document describes a real-world evidence framework that aims to improve the quality of real-world evidence informing our guidance. The framework does not set minimum standards for the acceptability of evidence. The framework is mainly targeted at those developing evidence to inform NICE guidance. It is also relevant to patients, those collecting data, and reviewers of evidence
Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making
Evidence-based recommendations on SEM Scanner 200 for preventing pressure ulcers.
Dexamethasone intravitreal implant for treating diabetic macular oedema (TA824)
Evidence-based recommendations on dexamethasone intravitreal implant (Ozurdex) for treating visual impairment caused by diabetic macular oedema in adults.
Degarelix for treating advanced hormone-dependent prostate cancer (TA404)
Evidence-based recommendations on degarelix (Firmagon) for advanced hormone-dependent prostate cancer in adults with spinal metastases.
This guide describes the process NICE uses to develop indicators from NICE quality standards, NICE guidance and NICE accredited sources
Evidence-based recommendations on pembrolizumab (Keytruda) for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiency in adults.
Evidence-based recommendations on SonoVue (sulphur hexafluoride microbubbles) for contrast-enhanced ultrasound imaging of the liver.
This guide describes the process NICE uses to develop NICE quality standards